How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England

摘要

I n The Lancet, the Early Breast CancerTrialists' Collaborative Group (EBCTCG) report meta-analyses of outcomes in 100 000 women with early breast cancer in more than 100 trials of adjuvant chemotherapy,1 which include the first EBCTCG meta-analyses of adjuvant taxane treatment. This study comes 35 years after the first report of the benefit of adjuvant chemotherapy,2 and is the 16th publication in the group's 28-year history of bringing together individual patient data from all randomised trials worldwide.3 The EBCTCG are to be commended for their ongoing commitment to this rigorous process and for their contribution to understanding of the long-term benefits and risks of treatment. We should also acknowledge the women whose participation made this overview possible.